TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ketamine in the Acute Phase of Suicidal Ideation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview~* The patient is able to understand how the study is carried out and the tests performed~* The patient is deemed capable of giving his/her informed consent~* The patient has been correctly informed~* The patient must have given his/her informed and signed consent.~* The patient must be insured or beneficiary of a health insurance plan.~* Presence of suicidal ideation according to the SSI score (score \> 3)~* Negative pregnancy test for women of childbearing age~Exclusion Criteria:~* The patient is participating in another interventional study~* Within the past three months, the patient has participated in another interventional study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection~* The patient is an adult under guardianship~* The patient refuses to sign the consent~* The patient is not able to understand the informed consent~* Pregnancy or breastfeeding~* History of schizophrenia or other psychotic disorders~* Presence of psychotic symptoms at initial interview~* Schizoid or schizotypic personality disorder~* Positive urine screening for illicit substances, excluding cannabis~* Substance dependence in the preceding month (excluding nicotine or caffeine)~* Concomitant treatment with electroconvulsive therapy~* Unstable somatic pathology~* Clinically significant anomalies found during clinical examination, biological test or ECG~* Non-stabilized hypertension or hypertension \> 180/100~* Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Patients randomized to this group will be treated via Ketamine infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of ketamine Intervention: Follow-up between perfusions Intervention: 2nd perfusion of ketamine Intervention: Follow-up after perfusions
- Placebo/Control (Type: PLACEBO_COMPARATOR): Patients randomized to this group will be treated via saline solution infusion.~Intervention: Baseline evaluation Intervention: 1st perfusion of saline Intervention: Follow-up between perfusions Intervention: 2nd perfusion of saline Intervention: Follow-up after perfusions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female ≥18 years of age at the screening visit~2. Clinical diagnosis of OA of the knee or hip based on the American College of Rheumatology criteria with radiologic evidence of OA (K-L score ≥2) for the index joint at the screening visit~3. Moderate to severe pain in the index joint defined as a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) average pain subscale score of ≥4~4. A history of 12 weeks of analgesic use for OA of the knee or hip~5. History of regular use of analgesic medications for OA pain~Key Exclusion Criteria:~1. History or presence at the screening visit of non OA inflammatory joint disease~2. History or presence on imaging of arthropathy, stress fracture, recent stress fracture, neuropathic joint arthropathy, hip dislocation, knee dislocation, congenital hip dysplasia with degenerative joint disease, extensive subchondral cysts, evidence of bone fragmentation or collapse, or primary metastatic tumor with the exception of chondromas or pathologic fracture during the screening period~3. Signs or symptoms of carpal tunnel syndrome within 6 months of screening~4. Patient is not a candidate for MRI~5. Is scheduled for a joint replacement surgery to be performed during the study period~6. Systemic (i.e., oral or intramuscular) corticosteroids within 30 days prior to the screening visit.~7. History or presence at the screening visit of multiple sclerosis, autonomic neuropathy, diabetic neuropathy, or other peripheral neuropathy, including reflex sympathetic dystrophy~8. History or diagnosis of chronic autonomic failure syndrome including pure autonomic failure, multiple system atrophy~9. Pregnant or breast-feeding women~10. Women of childbearing potential who have a positive pregnancy test result or do not have their pregnancy test result at baseline~Note: Other protocol defined Inclusion/Exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fasinumab dosing regimen 1 (Type: EXPERIMENTAL): None
- Fasinumab dosing regimen 2 (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saxagliptin Triple Oral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent~* Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c \> or = 7% and \< or = 10%) despite being on combination of metformin and sulfonylurea for at least 8 weeks prior to Visit 1~* BMI \< or = 40 kg/m2~Exclusion Criteria:~* Symptoms of poorly controlled diabetes including but not limited to marked polyuria and marked polydipsia with \> 10% weight loss in 3 months prior to entry, or other signs and symptoms~* History of diabetic ketoacidosis or hyperosmolar non-ketotic coma~* Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1 analogues, and/or other oral anti-diabetic agents (other than metformin or sulfonylurea)~* Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor~* Estimated CrCl \< 60 ml/min at Visit 2~* CHF (NYHA class III or IV) and/or LVEF \<40%~* Active liver disease and/or significant abnormal liver function defined as AST and/or ALT \> 3 x ULN and/or bilirubin \> 2.0 mg/dL at Visit 2.~* Creatine kinase \> or = 10 x ULN at Visit 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saxagliptin 5 mg once daily (Type: EXPERIMENTAL): None
- Placebo once daily (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~Patients must meet all of the following criteria to be eligible for the study:~1. Diagnosed with AF anytime in the baseline period or on the index date, also have definitive diagnosis of AF anytime in the baseline period, on the index date, or post-index period.~2. Prescribed one of the index OACs (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) on or after the day of AF diagnosis. The first observed prescription will be used to identify the patient's index date and treatment cohort~3. No use of the any OACs during the baseline period (the 180 days before the index date)~4. Age of 18 years or older on the index date.~Exclusion criteria~Patients meeting any of the following criteria will not be included in the study:~1. Having a diagnosis of valvular atrial fibrillation, post-operative atrial fibrillation, rheumatic atrial fibrillation or mechanical-valvular atrial fibrillation during the baseline and post-index period 2. Having a cardiac surgery procedure record during the baseline period 3. Having a joint replacement procedure record during the baseline period 4. Having a procedure of prosthetic heart valve during the baseline period 5. Having a diagnosis of venous thromboembolism during the baseline period 6. Female patients with pregnancy during the follow-up period 7. Patients prescribed off-label doses of OACs (per Japanese package insert of each OAC) or patients treated with OAC but in off-label or contraindicated manners.~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Inclusion criteria~  1. Postmenopausal women (one year after menses stop)~ 2. Confirmed diagnosis of breast cancer~ 3. Tumors with higher expression PR \> 50 % measured by IHC and PRA/RPB ratio equal or higher than 1.5 measured by WB~ 4. All clinical stages with tumor size greater than 1.5 cm to allow obtaining material from biopsy cores~ 5. OMS condition: 1 Adequate function of organs and systems~Hematopoietic parameters:~* Hemoglobin: 10 gr/mL~* Neutrophil counting: 1.500/mm3~* CD4 counting: 400/mm3~* Platelets counting: 100.000/mm3 Liver parameters~* Total albumin: 1.5 fold normal limit~* AST/ALT: 1.5 fold normal limit Renal~* Creatinine: 1.5 fold normal limit 6. Absence of other controlled disease 7. Patients willing to sign consent~Exclusion Criteria:~* Exclusion criteria~  1. Patients with no recommended surgery~ 2. Patients which have received any other treatment for this cancer~ 3. Patients expressing ER but expressing PRA/PRB levels lower than 1.5~ 4. Hepatitis infection (HBV o HCV)~ 5. HIV infection.~ 6. Cognitive alterations which limit the understanding of the protocol or compliance to the protocol~ 7. Prolonged QT/QTc basal interval

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Tablets of Mifepristone 200 mg p.o. once a day during 14 days between biopsy and surgery after confirming inclusion criteria

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with PMF or Post-PV/ET MF~* Patients with myelofibrosis requiring therapy~* Adequate bone marrow reserve~Exclusion Criteria:~* Received anti-cancer medications or investigational therapy in the past 14 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): All participants received oral ruxolitinib. Patients began treatment with either 10 mg twice a day (bid), 15 mg bid, 25 mg bid, 50 mg bid, 25 mg once a day (qd), 50 mg qd, 100 mg qd, or 200 mg qd, depending on the time period when they entered the study. The doses were titrated based on efficacy and safety to a maximum of 25 mg bid for patients who entered the study after sufficient dosing information had been obtained to define the maximum dose for patients in the study. Patients could continue receiving treatment indefinitely if receiving benefit at a dose that continues to maintain benefit but does not exceed a maximum dose of 25 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should have diagnosis of plaque-type psoriasis for at least 6 months prior to first administration of study agent (patients with concurrent psoriatic arthritis may be enrolled)~* Moderate-to-severe psoriasis scored as PASI \>= 10 at screening and at the time of first administration of ustekinumab~* Should currently receive (and have been receiving for at least 8 weeks directly prior to screening) systemic therapy with methotrexate at a dose of at least 10 mg/week but not exceeding 25 mg/week, with an inadequate response to this treatment (due to either efficacy or tolerability) and, in the judgment of the treating physician and patient, a treatment change is needed~* Women should take adequate birth control measures throughout the study and must agree to continue to use such birth control measures and not to become pregnant or plan to become pregnant for at least 15 weeks after the last dose of ustekinumab and for at least 6 months after the last dose of methotrexate~* Men must be using adequate birth control measures whilst receiving methotrexate and for 6 months after the last dose of methotrexate~Exclusion Criteria:~* Patients should not have non-plaque forms of psoriasis (eg, erythrodermic, guttate, or pustular)~* Should currently (and within 12 months) not receive ciclosporin, fumarates, PUVA, etanercept, efalizumab, infliximab, adalimumab or alefacept or other biologic or systemic therapy (and other therapy as indicated in the protocol)~* Women who are pregnant, breastfeeding, or planning pregnancy (both men and women) while enrolled in the study~* Have previously failed treatment with any therapeutic agent directly targeted at reducing IL-12 or IL-23, including, but not limited to, ustekinumab and ABT-874~* Active or latent Tuberculosis or other chronic or recurrent infectious disease~* Known history of lymphoproliferative disease~* Known malignancy or history of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Methotrexate Cessation (Type: EXPERIMENTAL): Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. The last dose of methotrexate will be taken anytime in the week prior to baseline (week 0).
- Gradual Reduction of Methotrexate (Type: ACTIVE_COMPARATOR): Patients will receive ustekinumab by SC injection at Weeks 0, 4, 16, 28 and 40. Patients will gradually reduce the dose of methotrexate over the 4 week period after week 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Birth Dose for Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn with weight more than 2000 grams~* Born to health mothers~* No sign of congenital disease~Exclusion Criteria:~* Low birth weight newborn~* Signs and Symptoms of febrile Illness/sepsis~* Congenital Malformation~* Signs of Cyanosis~* Difficulty in breathing

- Gender: ALL
- Minimum Age: 12 Hours
- Maximum Age: 8 Months
- Healthy Volunteers: t

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): After birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the intervention group were administered GSK's ® recombinant hepatitis B vaccine ENGERIX 10 micrograms (µ gm), intramuscular in the anterolateral part of either of thighs. This birth dose of hepatitis B was followed by zero dose oral polio vaccine as per hospital policy. Infants born to mother in the control group were given oral polio vaccine as per the hospital policy.
- Control Arm (Type: OTHER): In this arm of the study, after birth, one cc of intravenous blood was drawn from the peripheral veins of healthy newborn. The blood was immediately centrifuged, and serum was put in a plastic container, labeled with a unique identification number. The serum containers were frozen and then sent using a cold chain container, to Pakistan Medical Research Council laboratory at Jinnah Postgraduate Medical Center Karachi. The serum was tested for anti-hepatitis B surface antigen antibody on Enzyme Immunoassay (EIA) kit DS-EIA-Anti-HBsAg, manufactured by DSI S.r.I (Italy).~After obtaining a blood sample, infants born to mothers in the control group were given oral polio vaccine as per the hospital policy. Subsequent vaccinations were administered as per the expanded program on immunization schedule in Pakistan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety And Immunogenicity Study Of A 13-valent Pneumococcal Conjugate Vaccine In Japanese Subjects Aged 6 To 64 Years.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese males and females aged 6 to \<65 years at enrollment.~* Subjects with an increased risk of pneumococcal disease determined by documented medical history, physical examination, and clinical judgment of the investigator.~Exclusion Criteria:~* Previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt during study participation.~* End-stage disease including but not limited to metastatic malignancy, severe chronic obstructive pulmonary disease (COPD) requiring supplemental oxygen, or end-stage renal disease with or without dialysis.~* Graft-versus-host disease (GVHD), history of solid organ transplant within 6 months before investigational product administration or history of HSCT, or potential for solid organ transplant or HSCT during study participation.~* Receipt of cytotoxic chemotherapy or blood products within 3 months before investigational product administration or anti-B-cell antibodies within 6 months before investigational product administration through completion of study participation.~* Any contraindication to vaccination or vaccine components, including previous anaphylactic reaction to any vaccine or vaccine-related components.~* Documented S pneumoniae infection within the past 5 years before investigational product administration.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 13-valent pneumococcal conjugate vaccine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of dry eye for at least 6 months.~* Signs of moderate to severe dry eye~Exclusion Criteria:~* Women who are nursing or pregnant~* Participation in other studies within 30 days of screening visit~* Ocular disorders that may confound interpretation of study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment 1 (Type: EXPERIMENTAL): None
- Treatment 2 (Type: EXPERIMENTAL): None
- Treatment 3 (Type: EXPERIMENTAL): None
- Treatment 4 (Type: EXPERIMENTAL): None
- Active comparator (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ED90 of Remimazolam Loading Dose for Sedation in Patients Under Monitored Anesthetic Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ASA PS 1-3~* Patients who are scheduled to undergo upper/lower limb surgery under the monitored anesthetic care with remimazolam~Exclusion Criteria:~* Patients who refuse to participate in this study~* Patients with hypersensitivity to benzodiazepine or flumazenil~* Patients with severe renal/hepatic disease~* Patients with drug/alcohol abuse~* Patients who take antidepressants, anticonvulsants, psychoactive drugs chronically~* Patients with difficulty in communication~* Patients with severe obstructive sleep apnea or other airway problems~* Patients contraindicated to regional anesthesia~* Patients judged to be inappropriate for this study

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Remimazolam (Type: EXPERIMENTAL): A loading dose of remimazolam is administered for sedation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete